[1]
Shehab A, Bhagavathula AS, Abebe TB, et al. Patient adherence to novel oral anticoagulants (NOACs) for the treatment of atrial fibrillation and occurrence of associated bleeding events: A systematic review and meta-analysis. Curr Vasc Pharmacol 2019; 17: 341-9.
[3]
Arnet I, Kooij MJ, Messerli M, Hersberger KE, Heerdink ER, Bouvy M. Proposal of standardization to assess adherence with medication records: Methodology matters. Ann Pharmacother 2016; 50: 360-8.
[4]
Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study. J Thromb Haemost 2015; 13: 495-504.
[5]
Luger S, Hohmann C, Niemann D, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention-impact of the novel oral anticoagulants. Patient Prefer Adherence 2015; 9: 1695-705.
[6]
Beyer-Westendorf J, Förster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; 17: 530-8.